Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
09.10. | Ipsen's Iqirvo approved by MHRA to treat primary biliary cholangitis in adults | ||
09.10. | PMLiVE's T40 - results announced! | ||
08.10. | AstraZeneca/Avillion share positive phase 3 results for asthma rescue treatment Airsupra | ||
08.10. | J&J's Erleada shows overall survival benefit in head-to-head prostate cancer study | ||
08.10. | ICR researchers reveal benefits of personalised radiotherapy for bladder cancer patients | ||
07.10. | AstraZeneca gains rights to CSPC's lipid-lowering therapy in deal worth over $1.9bn | ||
07.10. | AbbVie shares promising late-stage results for Parkinson's disease candidate tavapadon | ||
07.10. | ABPI highlights importance of NHS-industry partnerships in improving patient outcomes | ||
04.10. | Bristol Myers Squibb's Opdivo regimen granted FDA approval in NSCLC | ||
04.10. | Chiesi Group invests €400m to establish biotech centre of excellence in Italy | ||
04.10. | Researchers develop new approach to target cells affected by motor neurone disease | ||
03.10. | Eli Lilly announces new $4.5bn US site for manufacturing and drug development | ||
03.10. | GSK receives CHMP recommendation for meningococcal disease vaccine Menveo | ||
03.10. | NHS England begins newborn screening programme to identify rare genetic conditions | ||
03.10. | Results from Global Pharmaceutical Customer Experience survey | ||
03.10. | How patients are transforming cancer care: insights from ESMO on patient-centric oncology | ||
03.10. | Stats without stories: why journalists aren't covering your data | ||
02.10. | Sanofi/Regeneron's Dupixent approved by FDA to treat uncontrolled COPD | ||
02.10. | Roche's Genentech acquires Regor Pharmaceuticals' CDK inhibitors for $850m upfront | ||
02.10. | J&J and Legend share long-term results for Carvykti in phase 3 multiple myeloma study | ||
02.10. | Bristol Myers Squibb announces positive data for Sotyktu in moderate-to-severe psoriasis | ||
02.10. | Strategy execution - ensuring it all fits together | ||
01.10. | Roche's injectable C5 inhibitor PiaSky recommended by NICE for rare blood disorder PNH | ||
01.10. | Johnson & Johnson's Yuvanci granted EC approval to treat pulmonary arterial hypertension | ||
01.10. | FDA approves IntraBio's Aqneursa to treat Niemann-Pick disease type C patients |